Horstmann Marcus, Patschan Oliver, Hennenlotter Jörg, Senger Erika, Feil Gerhard, Stenzl Arnulf
Department of Urology, Eberhard Karls University Tuebingen, Tuebingen, Germany.
Scand J Urol Nephrol. 2009;43(6):461-6. doi: 10.3109/00365590903296837.
The aim of the study was to investigate whether combinations of urine-based tumour markers including urinary cytology (Cytology or Cyt) increase the sensitivity in the detection of bladder cancer recurrence.
Urinary cytology, NMP22, UroVysion (FISH) and ImmunoCyt (uCyt+) were determined in 221 patients during the follow-up of non-muscle-invasive transitional cell carcinoma (NMI TCC) before cystoscopy (n = 49) or with the suspicion of TCC recurrence before transurethral resection of the bladder (n = 173). For all markers alone as well as in all possible combinations (multimarker panels, MPs) sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy were evaluated. MPs were considered positive if at least one marker was positive.
No malignancy was found in 108 patients, whereas recurrent TCC was confirmed in 113 patients. Sensitivity and specificity for Cytology were 84% and 62%, for NMP22 68% and 49%, for FISH 72% and 63%, and for uCyt+ 73% and 62%, respectively. The NPV was below 80% for all markers alone. Combinations of two and three markers increased the sensitivity as well as the NPV to over 90 and 80%, by reducing specificity to an average of 44% and 35%, respectively. The most sensitive combinations were NMP22, uCyt+ together with Cytology and FISH, and uCyt+ together with NMP22 (sensitivity for both combinations 98%). There was no further improvement when all four markers were combined.
Combinations of tumour markers increased the sensitivity and NPV in the detection of recurrence of NMI TCC. A stepwise approach of tumour marker determination may be used to reduce the frequency of follow-up cystoscopies at a reasonable risk.
本研究旨在调查包括尿细胞学检查(Cytology或Cyt)在内的基于尿液的肿瘤标志物组合是否能提高膀胱癌复发检测的敏感性。
在221例非肌层浸润性移行细胞癌(NMI TCC)患者的随访期间,于膀胱镜检查前(n = 49)或经尿道膀胱肿瘤电切术前怀疑TCC复发时(n = 173)测定尿细胞学、NMP22、UroVysion(荧光原位杂交,FISH)和免疫细胞化学(uCyt+)。对所有单独的标志物以及所有可能的组合(多标志物组,MPs)评估其敏感性、特异性、阳性预测值(PPV)、阴性预测值(NPV)和准确性。若至少有一个标志物呈阳性,则MPs被视为阳性。
108例患者未发现恶性肿瘤,而113例患者确诊为复发性TCC。尿细胞学检查的敏感性和特异性分别为84%和62%,NMP22为68%和49%,FISH为72%和63%,uCyt+为73%和62%。所有单独标志物的NPV均低于80%。两种和三种标志物的组合通过将特异性分别平均降低至44%和35%,使敏感性和NPV提高到90%以上和80%以上。最敏感的组合是NMP22、uCyt+与尿细胞学检查和FISH,以及uCyt+与NMP22(两种组合的敏感性均为98%)。当四种标志物联合使用时,未进一步提高敏感性。
肿瘤标志物组合提高了NMI TCC复发检测的敏感性和NPV。可采用逐步测定肿瘤标志物的方法,在合理风险下减少随访膀胱镜检查的频率。